Patients with malignant disease frequently develop anaemia. To investi
gate the role of erythropoietin (EPO) in this anaemia, serum levels we
re determined in patients with solid tumours. The study population con
sisted of 84 patients (44 males, 40 females) with solid tumours and 99
healthy control subjects, and 13/84 patients were anaemic. Serum EPO
was clearly elevated in the anaemic tumour patients, but this increase
was less than in patients suffering from iron deficiency anaemia. As
in iron deficiency anaemia, the correlation between EPO levels and hae
moglobin values was inverse. When compared to healthy control subjects
, the levels of EPO in the tumour patients without anaemia were decrea
sed. We conclude that there may be an inhibition in the expression or
secretion of EPO in patients with solid tumours which, as yet, has not
been further defined. Based on this, the treatment of anaemia in canc
er patients with erythropoietin appears promising.